Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Endometrial Neoplasms: early-phase trial registry
6 of 15 indexed Endometrial Neoplasms trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 6 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Endometrial Neoplasms: 15 US clinical trials tracked, 6 recruiting.
Endometrial Neoplasms is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 4 of these trials.
Enrollment posture brief
Registry condition endometrial-neoplasms
OPEN 6 | RECR 40% | LATE 3 | EARLY 9 | RANK #1140 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Achondroplasia (40% recruiting · 10 trials)
Endometrial Neoplasms lists 6 open slots (40% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Endometrial Neoplasms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Endometrial Neoplasms is recruiting below its size-band peers.
6 of 15 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Endometrial Neoplasms research.
Eli Lilly and Company accounts for 4 of 15 trials (26.7%). 11 distinct sponsors appear on at least one study for this condition label.
-
Typical Endometrial Neoplasms enrolment sits around 280 participants.
Median target enrolment is 280 among the 15 trials that report a genuine target (sentinel values excluded). 2 of those (13.3%) plan for fewer than 100 participants.
-
Endometrial Neoplasms research is mostly interventional.
14 interventional and 1 observational studies make up this index (93.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Eli Lilly and Company
NCT04956640
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Eli Lilly and Company
NCT06400472
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Eli Lilly and Company
NCT07114601
A Study of LY4175408 in Participants With Advanced Cancer
Eli Lilly and Company
NCT07046923
A Study of DM002 in Patients With Advanced Solid Tumors
Xadcera Biopharmaceutical (Suzhou) Co.
NCT06751329
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics
NCT06586957
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
Merck Sharp & Dohme
NCT04634877
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
AstraZeneca
NCT04269200
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Eisai
NCT04008797
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
Merck Sharp & Dohme
NCT05173987
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Seagen, a wholly owned subsidiary of Pfizer
NCT06003231
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
SystImmune
NCT06714617
Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors
Wake Forest University Health Sciences
NCT03935282
Pre-Clinical Models in Gynecological Tumors A Tissue Repository
University of New Mexi
NCT00250783
Time Restricted Eating (TRE) Among Native Hawaiian/Pacific Islander Women at Risk for Endometrial Cancer
University of Utah
NCT04763902
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 1 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Endometrial Neoplasms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Endometrial Neoplasms trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Endometrial Neoplasms page
15 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Endometrial Neoplasms trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eli Lilly and Company sponsors the most Endometrial Neoplasms trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Endometrial Neoplasms condition card totals 15 registered trials; most-linked intervention carboplatin; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.